Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck.

Bhatia A, Burtness B.

Cancers (Basel). 2017 Aug 31;9(9). pii: E113. doi: 10.3390/cancers9090113. Review.

2.

Jak3 is involved in CCR7-dependent migration and invasion in metastatic squamous cell carcinoma of the head and neck.

Zhang Z, Liu F, Li Z, Wang D, Li R, Sun C.

Oncol Lett. 2017 May;13(5):3191-3197. doi: 10.3892/ol.2017.5861. Epub 2017 Mar 14.

3.

Low CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma.

Xiong Y, Liu L, Wang J, Xi W, Xia Y, Bai Q, Qu Y, Long Q, Xu J, Guo J.

Oncotarget. 2017 Apr 11;8(15):25650-25659. doi: 10.18632/oncotarget.12827.

4.

Prognostic significance of CXCL12, CXCR4, and CXCR7 in patients with breast cancer.

Wu W, Qian L, Chen X, Ding B.

Int J Clin Exp Pathol. 2015 Oct 1;8(10):13217-24. eCollection 2015.

5.

CCL21-CCR7 promotes the lymph node metastasis of esophageal squamous cell carcinoma by up-regulating MUC1.

Shi M, Chen D, Yang D, Liu XY.

J Exp Clin Cancer Res. 2015 Dec 15;34:149. doi: 10.1186/s13046-015-0268-9.

6.

CCR7 enhances TGF-β1-induced epithelial-mesenchymal transition and is associated with lymph node metastasis and poor overall survival in gastric cancer.

Ma H, Gao L, Li S, Qin J, Chen L, Liu X, Xu P, Wang F, Xiao H, Zhou S, Gao Q, Liu B, Sun Y, Liang C.

Oncotarget. 2015 Sep 15;6(27):24348-60.

7.

The role of CCL21/CCR7 chemokine axis in breast cancer-induced lymphangiogenesis.

Tutunea-Fatan E, Majumder M, Xin X, Lala PK.

Mol Cancer. 2015 Feb 10;14:35. doi: 10.1186/s12943-015-0306-4.

8.

The role of chemoattractant receptors in shaping the tumor microenvironment.

Zhou J, Xiang Y, Yoshimura T, Chen K, Gong W, Huang J, Zhou Y, Yao X, Bian X, Wang JM.

Biomed Res Int. 2014;2014:751392. doi: 10.1155/2014/751392. Epub 2014 Jul 10. Review.

9.

Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment.

Mukaida N, Sasaki S, Baba T.

Mediators Inflamm. 2014;2014:170381. doi: 10.1155/2014/170381. Epub 2014 May 22. Review.

10.

A cytokine-delivering polymer is effective in reducing tumor burden in a head and neck squamous cell carcinoma murine model.

Lin Y, Luo J, Zhu WE, Srivastava M, Schaue D, Elashoff DA, Dubinett SM, Sharma S, Wu B, St John MA.

Otolaryngol Head Neck Surg. 2014 Sep;151(3):447-53. doi: 10.1177/0194599814533775. Epub 2014 May 13.

11.

Expression of CXCL10 is associated with response to radiotherapy and overall survival in squamous cell carcinoma of the tongue.

Rentoft M, Coates PJ, Loljung L, Wilms T, Laurell G, Nylander K.

Tumour Biol. 2014 May;35(5):4191-8. doi: 10.1007/s13277-013-1549-6. Epub 2014 Jan 7.

12.

Chemokines in tumor progression and metastasis.

Sarvaiya PJ, Guo D, Ulasov I, Gabikian P, Lesniak MS.

Oncotarget. 2013 Dec;4(12):2171-85. Review.

13.

Recently identified biomarkers that promote lymph node metastasis in head and neck squamous cell carcinoma.

Walk EL, Weed SA.

Cancers (Basel). 2011 Feb 22;3(1):747-72. doi: 10.3390/cancers3010747.

14.

Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-κB signaling.

Vander Broek R, Snow GE, Chen Z, Van Waes C.

Oral Oncol. 2014 Oct;50(10):930-41. doi: 10.1016/j.oraloncology.2013.10.005. Epub 2013 Oct 28. Review.

15.

Early expression of the fractalkine receptor CX3CR1 in pancreatic carcinogenesis.

Celesti G, Di Caro G, Bianchi P, Grizzi F, Marchesi F, Basso G, Rahal D, Delconte G, Catalano M, Cappello P, Roncalli M, Zerbi A, Montorsi M, Novelli F, Mantovani A, Allavena P, Malesci A, Laghi L.

Br J Cancer. 2013 Oct 29;109(9):2424-33. doi: 10.1038/bjc.2013.565. Epub 2013 Oct 1.

16.

The immune signature of CD8(+)CCR7(+) T cells in the peripheral circulation associates with disease recurrence in patients with HNSCC.

Czystowska M, Gooding W, Szczepanski MJ, Lopez-Abaitero A, Ferris RL, Johnson JT, Whiteside TL.

Clin Cancer Res. 2013 Feb 15;19(4):889-99. doi: 10.1158/1078-0432.CCR-12-2191. Epub 2012 Dec 19.

17.

Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer.

Moskowitz HS, Gooding WE, Thomas SM, Freilino ML, Gross N, Argiris A, Grandis JR, Ferris RL.

Oral Oncol. 2012 Nov;48(11):1136-45. doi: 10.1016/j.oraloncology.2012.05.015. Epub 2012 Jun 23.

18.

Chemokine receptor 7 (CCR7) gene expression is regulated by NF-κB and activator protein 1 (AP1) in metastatic squamous cell carcinoma of head and neck (SCCHN).

Mburu YK, Egloff AM, Walker WH, Wang L, Seethala RR, van Waes C, Ferris RL.

J Biol Chem. 2012 Jan 27;287(5):3581-90. doi: 10.1074/jbc.M111.294876. Epub 2011 Dec 12.

19.

Defective NF-κB signaling in metastatic head and neck cancer cells leads to enhanced apoptosis by double-stranded RNA.

Umemura N, Zhu J, Mburu YK, Forero A, Hsieh PN, Muthuswamy R, Kalinski P, Ferris RL, Sarkar SN.

Cancer Res. 2012 Jan 1;72(1):45-55. doi: 10.1158/0008-5472.CAN-11-1484. Epub 2011 Nov 4.

20.

Chemokine Receptor CCR3 Expression in Malignant Cutaneous Tumors.

Lee YJ, Kim DH, Lee SH, Nam HS, Roh MR, Cho MK.

Ann Dermatol. 2010 Nov;22(4):412-7. doi: 10.5021/ad.2010.22.4.412. Epub 2010 Nov 5.

Supplemental Content

Support Center